VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%
Fri, 22 Feb

VENUS REMEDIES has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

VENUS REMEDIES Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m931809691-14.6%-25.8%
Other incomeRs m1125-60.6%240.1%
TurnoverRs m933821695-15.3%-25.5%
ExpensesRs m754644643-0.1%-14.7%
Gross profitRs m17716547-71.3%-73.2%
DepreciationRs m8983830.0%-7.1%
InterestRs m8491943.4%12.1%
Profit before taxRs m53-125-4194.8%-2404.2%
TaxRs m0-5-60.0%
Profit after taxRs m58-119-1595.5%-2301.8%
Gross profit margin%19.020.46.9
Effective tax rate%0.0-161.64.4
Net profit margin%0.61.0-17.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 25.8% on a year-on-year (YoY) basis. The expenses were down by 14.7% YoY during the same period.
  • The company's operating profit declined by 73.2% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 6.9% in 3QFY19 as against 19.0% in 3QFY18.
  • Depreciation charges declined by 7.1% and finance costs increased by 12.1% YoY, respectively.
  • Other income increased by 240.1% YoY during the quarter.
  • Net profit for the quarter declined by 2301.8% YoY. Net profit margins during the quarter declined from 0.6% in 3QFY18 to -17.2% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 14.6% on a quarter-on-quarter (QoQ) basis. The expenses were down by 0.1% QoQ during the same period.
  • The company's operating profit declined by 71.3% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 6.9% in 3QFY19 as against 20.4% in 2QFY18.
  • Net profit for the quarter declined by 1595.5% QoQ, while net profit margins declined from 1.0% in 2QFY18 to -17.2% in 3QFY19.

To see how VENUS REMEDIES has performed over the last eight quarters, please visit here.

VENUS REMEDIES Share Price Performance

Over the last one year, VENUS REMEDIES share price has moved up from Rs 77.7 to Rs 31.0, registering a Loss of Rs 46.7 or around 60.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,571.8 (up 0.5%). Over the last one year it has moved down from 13,958.5 to 13,571.8, a gain of 387 points (down 2.8%).

Overall, the S&P BSE SENSEX is up 6.0% over the year.

Current Valuations

At the current price of Rs 31.0, the price to book value (P/BV) ratio of VENUS REMEDIES stands at 0.1 times.

Equitymaster requests your view! Post a comment on "VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%". Click here!

  

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution(Profit Hunter)

Mar 5, 2021

This could be the biggest wealth creator of the decade.

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Mar 9, 2021 02:56 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ACTAVIS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS